SCHEMBL31713855

SCHEMBL31713855

CCc1cc(=O)n2nc(C3CC3)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ MAPT P10636 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ MCHR1 Q99705 1/20 0.39
▸ PTGDR2 Q9Y5Y4 2/20 0.38
▸ TRPV1 Q8NER1 2/20 0.38
▸ AKR1B1 P15121 1/20 0.38
▸ ORAI1 Q96D31 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ TRPA1 O75762 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31664555 0.87 KDM4E (0.43) KDM4EMAPTTP53AKR1B1MEN1
SCHEMBL31713877 0.86 KDM4E (0.44) KDM4EMAPTTP53SMN1; SMN2AKR1B1
SCHEMBL31713938 0.83 KDM4E (0.41) KDM4EMAPTTP53SMN1; SMN2RXFP1
SCHEMBL31713851 0.82 PTGDR2 (0.42) KDM4EMAPTTP53SMN1; SMN2RXFP1
SCHEMBL31713883 0.79 WRN (0.49) KDM4EMAPTTP53AKR1B1MEN1
SCHEMBL25037269 0.79 KDM4E (0.43) KDM4EMAPTTP53SMN1; SMN2RXFP1
SCHEMBL31664544 0.78 KDM4E (0.43) KDM4EMAPTTP53RXFP1AKR1B1
SCHEMBL31713890 0.77 MAPT (0.39) KDM4EMAPTTP53MCHR1PTGDR2
SCHEMBL31713857 0.74 PTGDR2 (0.42) KDM4EMAPTTP53SMN1; SMN2RXFP1
SCHEMBL25035250 0.73 ACHE (0.44) KDM4EMAPTTP53RXFP1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL KDM4E 3651/4885MAPT 4634/4885TP53 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback